CasNo： 2381089-83-2
|
Description |
Retatrutide, also known by its experimental designation LY3437943, appears to be a drug in development for the treatment of obesity. It belongs to the class of gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptor agonists. These hormones play roles in glucose metabolism, appetite regulation, and energy balance, making them potential targets for the treatment of obesity. |
|
Uses |
Retatrutide is described as a single peptide with agonist activity at the GIP, GLP-1, and glucagon receptors. These receptors are involved in the regulation of glucose levels, insulin release, and energy homeostasis. As of the provided information, Retatrutide is in the investigational stage, and it is being studied in a Phase 3 clinical trial. The trial is expected to conclude in 2025 or 2026. The drug is mentioned as having the potential to treat obesity and Type 2 Diabetes (T2D). The development of drugs that target multiple hormonal pathways is a common strategy for addressing the complex nature of obesity. Retatrutide is noted to be suitable for once-weekly injection, which could be advantageous for patient adherence to treatment. |
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group.
More than 85% of obese participants with fatty liver disease in a clinical trial of the experimental drug retatrutide reduced their liver fat to the point where they would no longer be classified as having fatty liver disease, according to the Virginia Commonwealth University hepatologist leading the sub-study. Sanyal, who has served as a consultant to Lilly, says the research findings show retatrutide could become a “bottom up” therapy for at-risk patients, preventing liver disease from progressing and possibly reversing it.